Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(2.09) per share which missed the analyst consensus estimate of $(1.25) by 67.2 percent. This is a 39.33 percent decrease over losses of $(1.50) per share from the same period last year.